Italian clinicians analysed the clinical and biological data from a large series of cases of sporadic late-onset nemaline myopathy (SLONM):
- they added their own cases (5) to those in the literature, giving a total of 144 patients,
- 47% of whom had been initially diagnosed with SLONM with monoclonal gammopathy, which was absent in the other cases;
- these patients, known as SLNOM-MGUS, had more severe clinical manifestations, more frequently had nemalines visible on muscle biopsy, and responded better to immunotherapy.
This work is useful for better understanding this acquired myopathy, for which there are still no reliable biomarkers available to date.
